News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,958 Results
Type
Article (14300)
Company Profile (281)
Press Release (254377)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79726)
Career Advice (153)
Deals (13258)
Drug Delivery (36)
Drug Development (50548)
Employer Resources (31)
FDA (5769)
Job Trends (5186)
News (144828)
Policy (10070)
Tag
Academia (919)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21715)
ALS (64)
Alzheimer's disease (849)
Antibody-drug conjugate (ADC) (100)
Approvals (5797)
Artificial intelligence (125)
Autoimmune disease (18)
Automation (5)
Bankruptcy (105)
Best Places to Work (4591)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (155)
Cancer (1488)
Cardiovascular disease (117)
Career advice (134)
Career pathing (2)
CAR-T (118)
Cell therapy (333)
Cervical cancer (8)
Clinical research (41191)
Collaboration (543)
Compensation (263)
Complete response letters (13)
COVID-19 (1035)
CRISPR (42)
C-suite (166)
Cystic fibrosis (77)
Data (1535)
Denatured (11)
Depression (31)
Diabetes (139)
Diagnostics (1302)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (90)
Earnings (29916)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48745)
Executive appointments (464)
FDA (6483)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (498)
Gene editing (97)
Generative AI (10)
Gene therapy (255)
GLP-1 (367)
Government (1085)
Grass and pollen (2)
Guidances (27)
Healthcare (6630)
Huntington's disease (22)
IgA nephropathy (25)
Immunology and inflammation (92)
Indications (20)
Infectious disease (1100)
Inflammatory bowel disease (117)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (67)
Interviews (17)
IPO (7279)
IRA (11)
Job creations (884)
Job search strategy (127)
Kidney cancer (7)
Labor market (5)
Layoffs (212)
Leadership (4)
Legal (1397)
Liver cancer (33)
Lung cancer (205)
Lymphoma (104)
Machine learning (3)
Management (7)
Manufacturing (141)
MASH (54)
Medical device (2626)
Medtech (2627)
Mergers & acquisitions (6311)
Metabolic disorders (391)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (69)
Neuropsychiatric disorders (25)
Neuroscience (1262)
NextGen: Class of 2025 (2031)
Non-profit (866)
Now hiring (21)
Obesity (194)
Opinion (103)
Ovarian cancer (63)
Pain (44)
Pancreatic cancer (56)
Parkinson's disease (121)
Partnered (8)
Patents (131)
Patient recruitment (80)
Peanut (35)
People (25727)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14525)
Phase II (19138)
Phase III (12146)
Pipeline (819)
Policy (46)
Postmarket research (855)
Preclinical (6142)
Press Release (30)
Prostate cancer (62)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (294)
Real estate (1430)
Recruiting (12)
Regulatory (8678)
Reports (15)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (61)
Series A (98)
Series B (63)
Service/supplier (1)
Sickle cell disease (40)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1979)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (9)
The Weekly (36)
Vaccines (215)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Last 7 days (521)
Last 30 days (1418)
Last 365 days (19477)
2025 (6374)
2024 (20597)
2023 (22459)
2022 (26864)
2021 (27851)
2020 (23401)
2019 (16303)
2018 (11797)
2017 (13773)
2016 (11879)
2015 (14398)
2014 (10439)
2013 (7524)
2012 (7559)
2011 (7654)
2010 (7456)
Location
Africa (149)
Alabama (42)
Alaska (2)
Arizona (54)
Arkansas (5)
Asia (17361)
Australia (2938)
California (3892)
Canada (1149)
China (361)
Colorado (149)
Connecticut (152)
Delaware (108)
Europe (37331)
Florida (468)
Georgia (119)
Idaho (16)
Illinois (234)
India (10)
Indiana (98)
Iowa (2)
Japan (75)
Kansas (62)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (479)
Massachusetts (3100)
Michigan (70)
Minnesota (146)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (18)
New Hampshire (14)
New Jersey (974)
New Mexico (12)
New York (1051)
North Carolina (558)
North Dakota (5)
Northern California (1717)
Ohio (112)
Oklahoma (9)
Oregon (21)
Pennsylvania (748)
Puerto Rico (6)
Rhode Island (19)
South America (210)
South Carolina (4)
Southern California (1498)
Tennessee (25)
Texas (451)
United States (13374)
Utah (53)
Virginia (80)
Washington D.C. (30)
Washington State (354)
Wisconsin (15)
268,958 Results for "pearl therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Pearl Bio Inks Collaboration with Merck to Discover Novel Engineered Biologics
Pearl Bio today announced that it has entered a license, collaboration and option agreement with Merck, known as MSD outside of the United States and Canada, to discover biologic therapies comprising non-standard amino acids.
March 12, 2024
·
2 min read
Business
Merck Bets Potential $1B on Pearl Bio’s Genomically Recoded Organisms
Synthetic biology company Pearl Bio announced Tuesday it has entered into a license and collaboration agreement with Merck to discover biologic therapies comprising non-standard amino acids.
March 12, 2024
·
2 min read
·
Nick Paul Taylor
Genetown
Pearl Bio Secures Breakthrough IP for Multi-Functionalized Biologics
Pearl Bio , a synthetic biology company backed by Khosla Ventures, is recoding life to create a new era of biologics and biomaterials.
June 20, 2023
·
2 min read
Pharm Country
PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has been named the winner of 2023 EURORDIS Black Pearl Company Award for Innovation.
February 3, 2023
·
2 min read
Business
Dr. Pearl Huang Named CEO of Novartis-Backed Dunad Therapeutics (Updated)
Pearl Huang, Ph.D, has been appointed the CEO of U.K.-based Dunad Therapeutics, a Novartis-backed biopharmaceutical startup.
June 28, 2022
·
2 min read
·
Hannah Chudleigh
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine
Data presented at the European Academy of Neurology Congress 2023 Teva Pharmaceutical Industries Ltd. announces further positive data from the pan-European PEARL study investigating the impact of AJOVY® on the prevention of migraine in a real-world setting,1 due to be completed in 2024.
June 30, 2023
·
10 min read
Drug Development
Maggie’s Pearl Initiates Phase III Clinical Trial for Treatment of Patients with PMM2-CDG
Maggie’s Pearl, a joint venture between Perlara, Maggie’s Cure, and the Mayo Clinic, has started a Phase III clinical treatment trial to evaluate safety, tolerability, and clinical and metabolic improvement of pediatric subjects with PMM2-CDG (formerly known as Congenital Disorder of Glycosylation Type 1a) on oral epalrestat therapy versus a placebo.
January 9, 2023
·
2 min read
Pharm Country
Pearl Health raises $75M Series B led by a16z to accelerate growth and innovation in value-based care
Pearl Health, a leading technology company focused on physician enablement and risk bearing in value-based care, today announced that it has raised $75 million in its oversubscribed Series B funding round, led by Andreessen Horowitz’s Growth Fund and Viking Global Investors, with participation by AlleyCorp, SV Angel’s Growth Fund, and other leading investors.
January 26, 2023
·
5 min read
Press Releases
Historic achievement: FDA approval of Abeona Therapeutics’ ZEVASKYN accelerates momentum and expands treatment options for the EB community.
April 29, 2025
·
7 min read
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab)
Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria.
June 24, 2022
·
9 min read
1 of 26,896
Next
